Vincristine

證據等級: L5

預測適應症: 3 個

Vincristine: From Leukemia and Lymphoma to Ganglioneuroblastoma

One-Sentence Summary

Vincristine is a vinca alkaloid cytotoxic agent widely established as backbone chemotherapy for acute leukemia, lymphoma, and pediatric solid tumors, though it currently holds no Philippines FDA registration. The TxGNN model predicts it may be effective for Ganglioneuroblastoma, with 4 clinical trials and 6 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not registered in the Philippines; globally established use in leukemia, lymphoma, and pediatric solid tumors
Predicted New Indication	Ganglioneuroblastoma
TxGNN Prediction Score	99.31%
Evidence Level	L2
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacological knowledge, Vincristine is a vinca alkaloid that inhibits microtubule polymerization by binding to β-tubulin, thereby disrupting mitotic spindle formation and inducing G2/M cell cycle arrest followed by apoptosis. Because this mechanism directly targets actively dividing cells, tumors with high mitotic rates are inherently sensitive to vincristine.

Ganglioneuroblastoma (GNB) originates from neural crest cells and sits within the neuroblastoma (NBL) differentiation spectrum. These tumors share key proliferative drivers with neuroblastoma — including MYCN amplification and ALK mutations — that sustain rapid cell division. This biological overlap makes vincristine’s anti-mitotic mechanism directly applicable, and GNB is routinely co-enrolled in high-risk neuroblastoma clinical trials where vincristine forms a core component of the induction chemotherapy backbone.

The TxGNN prediction therefore reflects existing clinical practice rather than purely speculative repurposing. Multiple ongoing Phase 3 trials (NCT03126916, NCT06172296) explicitly include ganglioneuroblastoma within their high-risk neuroblastoma populations, and at least one Phase 2 pilot trial (NCT03786783) directly evaluates a vincristine-containing induction regimen in this population. The prediction score of 99.31% is consistent with this well-established mechanistic and clinical overlap.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03786783	Phase 2	Active, Not Recruiting	42	Pilot trial evaluating dinutuximab + GM-CSF combined with induction chemotherapy for high-risk neuroblastoma/GNB; vincristine is a core component of the induction backbone — the most directly relevant trial for this indication
NCT03126916	Phase 3	Recruiting	750	¹³¹I-MIBG or lorlatinib added to intensive multimodal therapy (COG ANBL series, vincristine-containing induction) for newly diagnosed high-risk neuroblastoma/ganglioneuroblastoma
NCT06172296	Phase 3	Recruiting	478	Dinutuximab added to intensive induction therapy for newly diagnosed high-risk neuroblastoma; vincristine serves as induction control arm backbone
NCT01798004	Phase 1	Completed	150	Myeloablative busulfan/melphalan consolidation following vincristine-containing induction chemotherapy for newly diagnosed high-risk neuroblastoma (including GNB nodular subtype)

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31342649	2019	Prospective Clinical Trial	Pediatric Blood & Cancer	Japan Children’s Cancer Group (JN-L-10) prospective trial using image-defined risk factors to guide surgical timing in low-risk neuroblastoma/GNB; supports risk-adapted management strategy
7421294	1980	Retrospective Case Series	J Thoracic and Cardiovascular Surgery	31 patients with isolated intrathoracic ganglioneuroblastoma followed up to 25 years; surgery, radiotherapy, and chemotherapy all evaluated as treatment modalities
8255850	1993	Case Report	Postgraduate Medical Journal	Unresectable spinal ganglioneuroblastoma achieving histologically proven complete remission with combination chemotherapy including vincristine (+ doxorubicin, cyclophosphamide, etoposide, ifosfamide, cisplatin) — no radiotherapy required
15701990	2005	Case Report	J Pediatric Hematology/Oncology	Ganglioneuroblastoma presenting with obstructive jaundice; treated with chemotherapy explicitly including vincristine, cisplatin, pirarubicin, and cyclophosphamide with documented response
8888754	1996	Case Report	J Pediatric Hematology/Oncology	Stage 4 multifocal ganglioneuroblastoma with rare gastric involvement in a female infant; documents clinicopathological characteristics
3071124	1988	Case Report	Acta Urologica Japonica	Adult adrenal ganglioneuroblastoma with giant regional lymph node metastasis in a 21-year-old; multimodality treatment including chemotherapy documented

Philippines Market Information

Vincristine is currently not registered in the Philippines. No FDA Philippines licenses are on record (total registrations: 0). Any clinical use would require special import authorization or compassionate use approval from the Philippines FDA.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Vinca alkaloid class (microtubule inhibitor)
Myelosuppression Risk	Moderate; primarily leukopenia; thrombocytopenia and anemia less pronounced compared to other cytotoxics
Emetogenicity Classification	Low to minimal
Monitoring Items	CBC with differential (each cycle), neurological assessment for peripheral neuropathy (dose-limiting toxicity), liver function tests (hepatic CYP3A4 metabolism), constipation/ileus surveillance
Handling Protection	Must follow cytotoxic drug handling regulations; critical safety alert: intrathecal administration is uniformly fatal — must follow ISMP and WHO mandatory labeling/dispensing safeguards for vincristine (dedicated “For IV Use Only” overwrap)

Safety Considerations

Please refer to the package insert for safety information.

Philippines FDA package insert data, label warnings, and contraindications were not available in this Evidence Pack. Drug interaction data was also not retrievable (DDI query returned no results). A full safety review obtaining the approved product monograph is required before any clinical use consideration.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Vincristine is already embedded as standard induction chemotherapy in multiple active Phase 3 trials that explicitly enroll ganglioneuroblastoma patients within high-risk neuroblastoma cohorts, and case reports document complete remission in GNB treated with vincristine-containing regimens. The prediction reflects established clinical practice; the primary barrier to use in the Philippines is the lack of local registration, not insufficient evidence.

To proceed, the following is needed:

Philippines FDA registration or special import/compassionate use authorization (drug currently not marketed locally)
Full safety review: obtain and parse Philippines FDA-approved or internationally recognized package insert for warnings, contraindications, and drug-drug interactions
Mechanism of action documentation via DrugBank API query (DG002 remediation)
Formal pharmacovigilance and risk management plan for cytotoxic agent use, with special attention to pediatric dosing protocols
Mandatory intrathecal error prevention protocol: implement ISMP-recommended “For IV Use Only” overwrap and separate dispensing workflow before any institutional use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.